Exosomes from Cancer Cells Could Predict Immunotherapy Responses
Immune-Evasion Mechanism May Help Explain the Differences in Responses to Immunotherapy
Commercializing Gene Therapies
Using High-Touch Services to Enhance Patient Outcomes
Improving CRISPR-Cas9’s Rate of Homology-Directed Repair
Integrated DNA Technologies Suggests Strategies to Boost Efficiency, Avoid Blunt-End Incorporation, and Reduce Toxicity
What the Top 10 Biopharma CEOs Are Making
Surging Markets Drive Double- and Triple-Digit Percentage Gains for Compensation
For full access to this article login to GEN Select now.
Ready, Aim, CRISPR (or RNAi)
When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
- Recent progress in probing gene function via the RNAi and CRISPR methods were a strong theme of the Discovery On Target conference, which took place last month in Boston. Both methods enable researchers to impair the function of a targeted gene. With RNAi (short for RNA interference), molecules ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.